Top Stories
Remlifanserin "narrowly missed" the primary endpoint of the Phase II RADIANT study, but Acadia says it saw "meaningful and consistent efficacy trends."
KTX-0141 is a small-molecule positive allosteric modulator of tropomyosin receptor kinase B (TrkB), building on research out of the University of Helsinki.
The deal follows a $787-million financing for Earendil, backed by Sanofi and Pfizer.
The company reported one-year data showing durable clinical responses and a favourable safety profile for miv-cel in stiff person syndrome and generalised myasthenia gravis.
The collaboration will utilise Atavistik's AMPS drug discovery platform and expertise in allosteric drug discovery.
Conference News
REDWOOD CITY, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare rare disease company focused on treating refractory hypogl...
New findings highlight the therapy’s ability to preferentially destroy MGMT-positive tumor cells, the specific population that survives standard treatments and drives disease recurrence.TAIPEI, Taiwan...
104 IPF patients enrolled in US and South Korea as global Phase 2 trial progresses toward completionStudy includes both antifibrotic-treated and untreated patients; top-line data expected in H1 2027Fi...
Oral presentation of the results from the RAMP 201J study of avutometinib plus defactinib in recurrent LGSOC in Japanese patientsNew external control arm analysis of avutometinib plus defactinib versu...
AUSTIN, Texas--(BUSINESS WIRE)--Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced an upcoming presentation ...
